GT Biopharma (GTBP) Accounts Payables (2010 - 2026)

GT Biopharma (GTBP) has reported Accounts Payables for 17 consecutive years, with $253000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 89.37% year-over-year to $253000.0; the TTM figure through Mar 2026 stood at $253000.0 (down 89.37% YoY), while the FY2025 annual figure was $748000.0, down 80.59% from the prior year.
• Accounts Payables declined to $253000.0 in Q1 2026 per GTBP's latest filing, from $748000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $8.1 million in Q1 2022 and bottomed at $253000.0 in Q1 2026.
• Historically, Accounts Payables has averaged $2.5 million across 5 years, with a median of $2.5 million in 2024.
• Annual changes were most pronounced in 2023 — Accounts Payables soared 325.39% — and 2026, when it plunged 89.37%.
• GT Biopharma's Accounts Payables stood at $3.1 million in 2022, then surged by 37.83% to $4.3 million in 2023, then dropped by 10.98% to $3.9 million in 2024, then tumbled by 80.59% to $748000.0 in 2025, then sank by 66.18% to $253000.0 in 2026.
• Business Quant data shows GTBP's Accounts Payables at $253000.0 in Q1 2026, $748000.0 in Q4 2025, and $769000.0 in Q3 2025.